Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Enterprise Value (2019 - 2026)

10x Genomics' Enterprise Value history spans 8 years, with the latest figure at -$523.4 million for Q4 2025.

  • On a quarterly basis, Enterprise Value fell 33.05% to -$523.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$523.4 million, a 33.05% decrease, with the full-year FY2025 number at -$523.4 million, down 33.05% from a year prior.
  • Enterprise Value hit -$523.4 million in Q4 2025 for 10x Genomics, down from -$482.1 million in the prior quarter.
  • Over the last five years, Enterprise Value for TXG hit a ceiling of -$222.4 million in Q4 2022 and a floor of -$640.1 million in Q2 2021.
  • Historically, Enterprise Value has averaged -$444.3 million across 5 years, with a median of -$422.6 million in 2023.
  • Biggest five-year swings in Enterprise Value: surged 62.14% in 2022 and later tumbled 74.79% in 2023.
  • Tracing TXG's Enterprise Value over 5 years: stood at -$587.4 million in 2021, then surged by 62.14% to -$222.4 million in 2022, then tumbled by 74.79% to -$388.7 million in 2023, then dropped by 1.21% to -$393.4 million in 2024, then plummeted by 33.05% to -$523.4 million in 2025.
  • Business Quant data shows Enterprise Value for TXG at -$523.4 million in Q4 2025, -$482.1 million in Q3 2025, and -$447.3 million in Q2 2025.